VESALIUS-CV Evolocumab improves CV outcomes in high risk primary prevention and secondary prevention without prior event. My take⬇️ #LateBreakers #AHA2025 @NEJM https://t.co/JRFjA6Qeqo

#AHA2025 Interesting data presented today by @JohnKastelein: The CETP inhibitor #Obicetrapib promotes striking ⬇️ in the concentration of small dense LDL particles. Potentially a convenient association to statins in pts with diabetes and/or CKM syndrome? Looking fwd to #PREVAIL

No benefit from beta-blockers in patients with recent myocardial infarction and LVEF equal or greater than 50%. #AHA2025 IPD meta-analysis of 5 RCTs including 17,801 patients (REBOOT, REDUCE-AMI, BETAMI, DANBLOCK, and CAPITAL-RCT). @Borjaibanez1 @dan_atar @RosselloXavier

Next week offers another opportunity to expand your knowledge! Our EAS webinar on diet is finally here! This session explores the relationship between ultraprocessed foods and cardiovascular disease (CVD), addressing common misconceptions and presenting evidence-based insights.

25yo 👩🏻 Right sided enlargement What is your diagnosis? 🗡️ #whyCMR #cardioTwitter ⁦@benayozbay⁩

1 day left! Tomorrow: first-ever #EASLATAM webinar on AI in CV prevention 🤖❤️ 🗓 Nov 6 🕕 18:00 CET 🎟 Free to join Speakers: @ChristopheStevens & Dr Efraín Gómez Chair: Luz Clemencia Zárate-Correa Don’t miss insights on ML, digital health & CVD prevention! 🚀 register:

It's time for the second EAS-LatAm webinar this year! From smarter risk prediction to personalized patient follow-up, AI and digital health are revolutionizing cardiovascular disease prevention. Explore how innovative, data-driven solutions are transforming the way clinicians

The Lipid Clinic Network local webinars on the Focused Update are tailored sessions designed to support national dissemination of the new guidance, adapt it to local clinical priorities, and foster collaboration between international experts and national networks. Each webinar

Looking forward to welcoming you in April at #ESCPrev26 💚  Step into the heart of #cvprev by registering early for the best savings, and submit your abstract by 20 Nov and clinical case by 27 Nov. 🔗Submit: https://t.co/eJOA5J0nNS 🔗Register: https://t.co/rZXeWZG5ky

My new paper in the Anatolian J of Cardiology: The hidden burden of premature CVD in a national leader—Mustafa Kemal Atatürk—through archival source & modern clinical reasoning. Early MI episodes (1923–27), familial risk, infections, & lifestyle paint a complex

So happy to be among HoFH experts from the Gulf region and to share our real-world experiences with HoFH & treatment challenges. Turkiye, MENA Region, and Gulf Region have the highest number of HoFH patients. Together, we can really make a real difference for our pts! 💪

When @atherosociety and @society_eas meet , Together , we can CHANGE Pleased to meet @MeralKayikcoglu in Muscat today .

Liv T Nordestgaard et al here show that genetic lowering of non-HDL cholesterol via HMGCR, NPC1L1, and CETP reduces the risk of dementia - just published in Alzheimer's & Dementia: https://t.co/ovluLKMox3 The totality of data to come to this conclusion is impressive:

https://t.co/w1t9kQEwGr

The EU High-Level Event on cardiovascular health is happening right now at the European Parliament 🇪🇺. Patients, policymakers & experts are coming together to highlight why early screening for FH and Lp(a) must become a European priority. @ProfKausikRay @KatiOorni

A new evidence for TG hypothesis! New in Circulation (Sep 23, 2025): #Hypertriglyceridemia causally drives AAA—dose-dependent effect, #LOX maturation/ECM impairment implicated; #ANGPTL3 ASO markedly attenuates AAA in mice. TG-rich lipoprotein management emerges as a therapeutic

Whether lowering Lp(a) reduces the risk of ASCVD and AVS progression has yet to be shown; the extent of Lp(a) lowering required for clinical benefit is also not known. In the absence of specific Lp(a)-lowering therapies, early risk factor management and more intensive LDL-C

Join us for a special session in recognition of Familial Hypercholesterolaemia (FH) Awareness Week. This webinar features the recorded session from EAS 2025 in Glasgow, highlighting key insights into FH diagnosis, treatment, and global strategies. Register here:

Important case presentation by @BNordestgaard at #ESCCongress2025 #WCCardio 👉 55-year-old man with ischemic heart disease & severe hypertriglyceridemia despite intensive lipid-lowering therapy. Final question to the audience: 🔻 What medication would you choose at TG 9.0 mmol/L

✨@DrMarthaGulati ’s presentation was excellent as always on the last day of #ESCCongress2025 #WCCardio Her key conclusions on imaging CAD in women vs men: •Imaging helps evaluate chest pain/IHD in women •Right test choice improves diagnosis & prognosis •CAC = valuable 1st